CRISPR Therapeutics AG research snapshot
CRSP AI stock analysis currently reads CRISPR Therapeutics AG as a pioneering gene-editing biotechnology company with a validated CRISPR/Cas9 platform, an approved product (CASGEVY partnered with Vertex for sickle cell disease and beta-thalassemia), and a deep pipeline spanning CAR-T cell therapies, in vivo gene editing, and type 1 diabetes. The stock closed at $53.35 on July 10, 2026, implying about $5.15 billion of equity value using 96.45 million shares. The company holds $2.44 billion in cash against $788 million in total debt, providing multi-year runway, but generated only $4.1 million in TTM revenue with a TTM net loss of $568.53 million. The main debate is whether CASGEVY commercial adoption scales, whether pipeline candidates deliver clinical proof-of-concept, and whether the stock can overcome its 22% short interest. This page is informational research and is not investment advice.
Current price
$53.35 close on July 10, 2026
Market cap
$5.15 billion using 96.45 million shares; price times shares verified with 0.00% variance
AI score
45 / 100
Rating
Pioneering CRISPR gene-editing platform with one approved product and deep pipeline, offset by pre-profitability, cash burn, high short interest, and binary clinical and commercial outcomes
Trend status
Price is above the 50-day moving average near $47.59 but well below the 52-week high of $78.48; momentum is mixed with elevated volatility and high beta near 1.70
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | CRISPR Therapeutics develops gene-based medicines using its CRISPR/Cas9 platform. The approved CASGEVY (with Vertex) treats sickle cell disease and beta-thalassemia, and the pipeline includes allogeneic CAR-T therapies for oncology and autoimmune indications, in vivo programs for cardiovascular disease, and a stem-cell derived candidate for type 1 diabetes. | Medium |
| Moat | The moat comes from foundational CRISPR/Cas9 intellectual property, deep scientific expertise, first-mover advantage in ex vivo gene editing with an approved product, and the Vertex partnership. However, multiple competitors (NTLA, BEAM, EDIT) have alternative gene-editing platforms, and CRISPR patent landscapes are complex and contested. | Medium |
| Management | CEO Samarth Kulkarni has led CRSP since 2018 and previously served as Chief Business Officer. Co-founder Emmanuelle Charpentier serves on the board. Management has secured strong partnerships (Vertex) and built a deep pipeline, but the key test is commercial execution of CASGEVY and capital allocation discipline as cash burn continues. | Medium |
| Financial trend | The company is pre-revenue in any meaningful sense with $4.1 million TTM revenue and TTM net loss of $568.53 million. Operating cash burn was approximately $400 million TTM. The $2.44 billion cash position provides runway into 2028+, but relies on cost discipline and potential milestone payments from Vertex. | High |
| Valuation | At $53.35, the stock trades at a market cap of $5.15 billion. With negative earnings, traditional P/E is not applicable. Enterprise value of about $3.5 billion (net of cash) prices in CASGEVY commercial potential plus pipeline optionality. The stock trades at 2.65x book value. The $67.78 consensus analyst price target suggests 27% upside from the current price. | Medium |
| Technical trend | Price at $53.35 is above the 50-day moving average near $47.59 but remains below the 200-day average. The 52-week range is $44.12 to $78.48. Beta near 1.70 indicates high volatility. RSI was in neutral territory in mid-2026. | Medium |
| Risk level | Risk is high. Pre-profitability, binary clinical outcomes, slow CASGEVY commercial adoption, elevated cash burn, 22% short interest, high beta, and competitive pressure from other gene-editing platforms all contribute. Dilution risk exists as the company may need to raise capital. | High |
| AI confidence | Data confidence is high for balance sheet items, share count, and market-cap verification, but lower for probability-adjusted pipeline valuation, CASGEVY peak sales estimates, and long-term price scenarios. | Medium data confidence |
| Investment certainty | Investment certainty is low to medium. The approved CASGEVY provides a floor of value, but the company is not yet profitable, clinical and commercial execution is unproven at scale, and the stock carries high volatility that may not suit all investors. | Low to medium |
CRSP AI stock forecast
The CRSP AI stock forecast uses a scenario framework around the $53.35 cutoff price. Because CRSP has negative EPS, traditional P/E-based scenario models are not applicable. The scenarios below are qualitative framework estimates based on CASGEVY adoption, pipeline progress, cash position, and analyst consensus, not promises or recommendations.
$80 to $110
More likely if CASGEVY adoption accelerates with expanded approvals (including pediatric), pipeline CAR-T and in vivo candidates show positive clinical data, the Vertex partnership expands, cash runway extends through milestone payments, and short interest decreases. This range is consistent with the high end of analyst price targets.
$45 to $70
More likely if CASGEVY grows steadily but slowly, pipeline candidates advance without major surprises, cash burn remains managed, and the stock trades in line with the $67.78 consensus analyst target with normal biotech volatility.
$25 to $40
More likely if CASGEVY adoption disappoints, pipeline candidates fail in clinical trials, competition from other gene-editing platforms intensifies, cash burn accelerates requiring dilutive financing, or the stock is pressured by sustained short interest.
CRSP AI technical analysis
CRSP AI technical analysis uses public market data available at the July 12, 2026 cutoff. The latest public close was $53.35 on July 10, 2026. MarketBeat reported a 50-day moving average near $47.59, a 52-week range of $44.12 to $78.48, and beta near 1.71. Technical levels describe market structure and do not predict the next price move.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $53.35 | Latest public close used for this page, dated July 10, 2026. |
| Near support | $47 to $50 | The 50-day moving average near $47.59 and the recent trading range form the first support band. |
| Key support | $44 to $45 | The 52-week low near $44.12 is a critical support level. A break below this would indicate significant technical weakness. |
| Near resistance | $56 to $62 | The July 2 high near $61.68 and the recent $56-62 trading range create the first overhead resistance zone. |
| Key resistance | $78.48 | The 52-week high is the next major reference point if price reclaims the $60+ zone. |
| 50-day moving average | About $47.59 | Price above this average indicates short-term trend support as of the July 10, 2026 data snapshot. |
| Momentum | RSI near neutral territory | RSI was neither overbought nor oversold in mid-2026, indicating no clear directional signal from momentum alone. |
| Volume | About 2.07 million shares on July 10, 2026 | Daily volume came from MarketBeat. Volume is typically above average on news events such as FDA decisions or clinical data releases. |
| Volatility | 52-week range $44.12 to $78.48; beta near 1.71 | The wide annual range and high beta make position sizing and predefined risk limits essential for any trading framework. |
| Invalidation | A sustained close below $44 | A decisive break below the 52-week low would invalidate the constructive technical setup and suggest further downside risk. |
CRSP AI trading strategy
The CRSP AI trading strategy is a rules-based framework, not personalized advice. Pair price action with CASGEVY sales data, clinical trial milestones, cash runway updates, analyst ratings, and short interest trends.
Consider a trend-following framework only after price reclaims and holds above the $56 to $62 resistance zone, confirmed by above-average volume, positive CASGEVY sales updates, or favorable clinical data readouts.
A close back below the 50-day average near $47.59 reduces confidence. A sustained close below the 52-week low at $44.12 invalidates the setup.
If price tests the $44 to $47 support zone while the company maintains its cash position and clinical pipeline remains on track, the risk/reward may favor a mean-reversion framework. However, biotech mean-reversion carries binary gap-down risk on negative news.
Do not average down automatically if cash burn accelerates, clinical trials fail, or CASGEVY adoption stalls. Biotech stocks can gap down significantly on binary news events.
Track CASGEVY quarterly sales, FDA label expansions, pipeline clinical data readouts (CAR-T, in vivo), Vertex partnership developments, cash runway, and short interest changes. Major events can produce outsized moves.
Reduce position size before binary clinical data events. A failed trial can destroy 30-50% of market value overnight, regardless of the underlying cash position.
Investment research summary
CRISPR Therapeutics sells gene-editing medicines built on the Nobel Prize-winning CRISPR/Cas9 technology. Customers are patients with serious genetic diseases. The company is paid through drug sales (CASGEVY partnership with Vertex) and potential future product revenues. The business model is high-risk, high-reward biotech drug development.
The moat rests on foundational CRISPR/Cas9 IP, first-mover advantage in ex vivo gene editing with an approved product, scientific talent, and the strategic Vertex partnership. However, competing platforms (base editing, prime editing, other CRISPR variants) and complex patent landscapes create competitive uncertainty.
The thesis fails if CASGEVY commercial adoption remains slow due to high cost, complex logistics, or competition. Pipeline candidates could fail in clinical trials. Cash burn could require dilutive financing. Vertex could deprioritize the partnership. Competitors with superior editing technologies could leapfrog CRISPR Therapeutics.
CEO Samarth Kulkarni has led the company since 2018 and brings business development and scientific expertise. Co-founder Emmanuelle Charpentier provides strategic guidance. Management has successfully partnered with Vertex, advanced multiple pipeline programs, and secured significant cash reserves. The key test is commercial execution and capital allocation as the company transitions from R&D to a commercial-stage biotech.
Gene editing represents a potential paradigm shift in medicine, moving from treating symptoms to correcting genetic causes. The CRISPR field has attracted massive investment and scientific talent. This positions CRSP within a long-term growth trend, but also subjects it to intense competition and rapid technological change.
At $53.35, CRSP trades at a $5.15 billion market cap with negative earnings. The enterprise value of about $3.5 billion (net of $2.44B cash minus $0.79B debt) prices in CASGEVY commercial potential and pipeline optionality. Margin of safety is limited given pre-profitability, binary risks, and 22% short interest. The $67.78 consensus analyst target suggests upside, but downside to $25-40 is possible in a bear scenario.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $53.35 close on July 10, 2026 | MarketBeat | July 12, 2026 |
| Shares outstanding | 96.45 million shares | MarketBeat and Motley Fool | July 12, 2026 |
| Market capitalization | $5.15 billion computed from $53.35 x 96.45 million shares | Financial rigor market-cap verification | July 12, 2026 |
| TTM revenue and net income | $4.10 million revenue and -$568.53 million GAAP net income | Yahoo Finance and Motley Fool | July 12, 2026 |
| Cash and total debt | $2.44 billion cash and $788 million total debt | Yahoo Finance, MarketBeat, Motley Fool (cross-verified) | July 12, 2026 |
| Enterprise value | About $3.5 billion (market cap minus net cash) | Computed from reported cash and debt figures | July 12, 2026 |
| TTM EPS | -$6.21 per share | Motley Fool | July 12, 2026 |
| Price-to-book ratio | 2.65x | MarketBeat | July 12, 2026 |
| Technical snapshot | 50-day average $47.59, 52-week range $44.12 to $78.48, beta 1.71 | MarketBeat statistics | July 12, 2026 |
| Short interest | 22.10% of float | MarketBeat | July 12, 2026 |
| Consensus analyst rating | Moderate Buy with $67.78 average price target (19 analysts) | MarketBeat | July 12, 2026 |
| CASGEVY approval | Approved for sickle cell disease and beta-thalassemia; expanded pediatric approval cleared by FDA July 2026 | Yahoo Finance news and FDA announcements | July 12, 2026 |
| CEO | Samarth Kulkarni, PhD (CEO since 2018) | MarketBeat and CRISPR Therapeutics website | July 12, 2026 |
This CRSP page is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are conditional scenarios based on available data and assumptions. Biotech investments carry high risk, including binary clinical outcomes, regulatory uncertainty, and potential capital dilution. Data can be delayed, incomplete, or wrong. Verify all information from original filings and consult a qualified financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
